The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

The trial, funded by NIH’s National Cancer Institute (NCI), aims to accelerate the discovery of more tailored treatments for these aggressive cancers of the blood and bone marrow.

“AML and MDS are a heterogeneous group of cancers that can progress very quickly. Treatment advances depend in part on the ability to rapidly identify which subtype of cancer each patient has so that treatments can be tested for their specific cancer,” said Richard F.

Little, M.D., of NCI’s Division of Cancer Treatment and Diagnosis.

Dr. Little is the NCI coordinator for the trial, known as the Myeloid Malignancies Molecular Analysis for Therapy Choice (myeloMATCH).

“The goal of myeloMATCH is to test combinations of drugs to treat the disease in a highly targeted way and to be able to start treatment quickly after diagnosis.”

Initially, people enrolled in the trial with newly diagnosed AML or MDS will undergo rapid genetic testing of their tumour samples.

Based on the molecular characteristics of their tumours, they will be matched to a substudy testing a treatment appropriate for the specific genetic changes and characteristics associated with their disease, if one is available, or to standard treatment if an appropriate substudy is not available.

If the initial treatment works to reduce a patient’s disease, they will undergo further genetic testing to match them to a subsequent substudy testing a treatment that is appropriate for the specific genetic changes associated with their remaining disease.

As the amount of a patient’s disease decreases, study investigators will use increasingly sensitive tools, such as biomarker assays, to identify appropriate treatments for any remaining cancer cells.

The myeloMATCH trial aims to enrol several thousand people within the first few years, with new substudies rolled out over time.

Blood and bone marrow samples collected from participants during the course of the trial will be used to develop and refine the assays, as well as understand what genetic changes might be associated with the development of resistance to a treatment.

myeloMATCH is being conducted by the National Clinical Trials Network, with the participation of the NCI Community Oncology Research Programme (NCORP).

Initial substudies will be led by the SWOG Cancer Research Network, the Alliance for Clinical Trials in Oncology, the ECOG-ACRIN Cancer Research Group, and the Canadian Cancer Trials Group.

The Frederick National Laboratory for Cancer Research, Fred Hutch Cancer Centre, and Children’s Hospital Los Angeles will provide clinical laboratory support for the substudies.

myeloMATCH is one of three next-generation precision medicine trials that NCI has under way.

ComboMATCH is testing the effectiveness of treating adults and children who have relapsed solid tumours with new drug combinations that target specific tumour alterations. ImmunoMATCH has launched a pilot study to determine whether prospective characterisation of the immune status of a tumour can be used to improve the response to targeted immunotherapy treatments, with plans to expand to larger studies in the future.

All three trials are successors to NCI-MATCH, NCI’s groundbreaking precision medicine clinical trial, which showed that people with advanced cancer may benefit from genomic sequencing to help plan their treatment.

Learn more about myeloMATCH and the substudies that are currently open.

Source: NIH/National Cancer Institute